

UCT-0012

REMARKS

Claims 33-82 are pending in the present application. Claims 35, 54, 56, 74 and 75 have been amended, and Claims 41-53, 62-72 and 79-82 have been withdrawn from consideration. Claims 33-40, 54-61, and 73-78 remain present for consideration upon entry of the present Amendment.

It is believed that the foregoing amendments and remarks fully comply with the Office Action and that the claims herein should now be allowable to Applicants. Accordingly, reconsideration and allowance is requested.

If there are any additional charges with respect to this Amendment or otherwise, please charge them to Deposit Account No. 06-1130 maintained by Applicants' attorneys.

Respectfully submitted,

TIMOTHY HLA ET AL

CANTOR COLBURN LLP

Applicants' Attorneys

By: Karen A. LeCuyer

Karen A. LeCuyer
Registration No. 51,928
Customer No. 23413

Date: September 18, 2002
Address: 55 Griffin Road South, Bloomfield, Connecticut 06002
Telephone: (860) 286-2929

UCT-0012

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Marked-up version of Claims 35, 54, 56, 74 and 75 follow:

35. (Amended/Marked-Up) The antisense oligonucleotide of claim 33 comprising
SEQ ID NO:1 or SEQ ID NO:2.

54. (Twice Amended/Marked-up) An antisense oligonucleotide, wherein the
antisense oligonucleotide inhibits the expression of a nucleic acid molecule encoding a
human EDG-3 receptor and wherein the antisense oligonucleotide includes the translational
initiation site of the EDG-3₊ receptor.

56. (Amended/Marked-Up) The antisense oligonucleotide of claim 54 comprising
SEQ ID NO:52.

74. (Amended/Marked-Up) The antisense oligonucleotide of claim 73 comprising
SEQ ID NO:1 or SEQ ID NO:2.

75. (Amended/Marked-Up) The antisense oligonucleotide of claim 73 comprising
SEQ ID NO:52.